Sickle Cell Disease: From Research to Clinical Management
Elevate your expertise and impact patient care by joining the EHA's pilot preceptorship on Sickle Cell Disease, designed for early-career hematology specialists, clinicians, lab technicians, and pathologists. This immersive program, part of the EHA Topics-in-Focus (TIF) initiative, provides a unique opportunity to gain cutting-edge knowledge through lectures and practical sessions led by top experts. Don't miss out on earning EBAH CME credits and enhancing your professional growth.
Applications closed at 23:59 (CEST) on August 18, 2024.
Dates
October 16–18, 2024
Location
Hôpital Necker-Enfants malades
149 rue de Sévres,
75015,
Paris
Chairs
- Prof Mariane de Montalembert, MD, PhD
- Dr Slimane Allali, MD, PhD
Purpose
The meeting is part of the EHA Topics-in-Focus (TIF) Hemoglobinopathies Program. The goal of this program is to:
- Educate and expand awareness of these increasingly common genetic diseases
- Develop and optimize a European regulatory framework for sickle cell disease and beta-thalassemia
The focus of this European regulatory framework will be:
- Education
- Predictive diagnostics
- Innovative treatment
Eligibility
To be eligible for the preceptorship, you must:
- Have a medical degree from an accredited institution.
- Have completed a specialty program in pediatrics, hematology, or a related field.
- Be board-certified or equivalent in your specialty.
- Have a personal or professional interest in Sickle Cell Disease and a commitment to improving the care and outcomes of patients with this condition.
- Have 1-2 years of professional experience managing patients with this condition.
- Be able to attend the preceptorship in person at the Hôpital Necker in Paris, France from October 16-18, 2024.
Attendees can be from any part of the world. Both EHA members and non-members can attend.
Application process
You'll be asked to submit a CV with your application form. The Sickle Cell Disease (SCD) Committee will use this document to check your background qualifications and determine your eligibility for the event.
Applications are evaluated on a rolling basis. You'll receive an email with the SCD Committee's final decision.
For any questions regarding the application process, please contact a.lebeda@ehaweb.org.
Participation costs and expenses
Participation is free of charge.
If you take part, you'll get access to:
- The full scientific program
- Meeting materials
- A dedicated session
All accommodation and logistical expenses will be reimbursed by EHA, up to the following maximum amounts:
- €750 for travel
- €750 for hotel accommodation
Program
You can find the full event details on the program page.
Topics that will be covered are:
- Laboratory tools to explore red blood cells
- Transfusion
- Hemoglobinopathy diagnosis
- Organization of care
- How to estimate the incidence, prevalence, and prognosis of sickle cell disease in high- and low-income countries
- SCD in adults
- New drugs in SCD
- Manual exchange transfusion and erythrocytapheresis
- Therapeutic education
- Neurological and hepatic complications
- Curative approaches: HSCT and gene therapy
Learning goals
By attending the meeting, you will:
- Gain more knowledge and skills in the diagnosis, management, and treatment of sickle cell disease
- Develop your ability to provide holistic, patient-centered, and culturally sensitive care to patients with sickle cell disease and their families
- Enhance your professional development and career prospects in pediatric hematology and advanced practice medicine
- Receive a certificate of completion
Continuing Medical Education credits
By attending, you'll also receive EBAH Continuing Medical Education (CME) credits.
CME is widely accepted and helps to encourage individual practitioners to:
- Maintain and develop professional knowledge and skills
- Keep up to date with the latest developments within the field
The meeting will be accredited according to the EBAH system. If you attend, you'll be eligible to receive one CME credit point for every hour of accredited activity.
Back